Drug Trial Radar · NCT07412496
A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Mar 31, 2026
Primary completion
Oct 4, 2026
Study completion Oct 4, 2026
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 58 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-masked study to evaluate the use of Topical Ocular BL1332 for the management of post-operative pain after Photorefractive Keratectomy (PRK) surgery.
Conditions
- Pain, Postoperative
Interventions
Topical Ocular BL1332 low doseDrug
Administered 5 times a day
Topical Ocular BL1332 high doseDrug
Administered 5 times a day
BL1332 Vehicle ophthalmic vehicleDrug
Administered 5 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular pain intensity following PRK surgeryTime frame: Assessed at a 24-hour period following PRK surgery
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Site 14
Scottsdale, Arizona
Site 3
Long Beach, California
Site 10
Pasadena, California
Site 11
San Diego, California
Site 15
Davie, Florida
Site 13
Brookline, Massachusetts
Site 5
Bloomington, Minnesota
Site 8
Amherst, New York
Site 9
Fargo, North Dakota
Site 6
West Fargo, North Dakota
Site 1
Sioux Falls, South Dakota
Site 2
Cedar Park, Texas
Site 12
Draper, Utah
Site 4
Salt Lake City, Utah
Site 7
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.